Krystal Biotech (NASDAQ:KRYS) Stock Price Up 7.1% on Analyst Upgrade

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price shot up 7.1% during trading on Thursday after Chardan Capital raised their price target on the stock from $212.00 to $218.00. Chardan Capital currently has a buy rating on the stock. Krystal Biotech traded as high as $186.69 and last traded at $188.63. 82,372 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 244,607 shares. The stock had previously closed at $176.17.

Several other equities research analysts have also commented on KRYS. HC Wainwright restated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday. Citigroup increased their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $207.67.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in Krystal Biotech during the 3rd quarter valued at about $40,000. Values First Advisors Inc. acquired a new stake in shares of Krystal Biotech in the third quarter valued at approximately $53,000. GF Fund Management CO. LTD. acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at approximately $95,000. Huntington National Bank lifted its position in Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after buying an additional 283 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in Krystal Biotech by 242.4% in the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after buying an additional 412 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

The business has a 50 day simple moving average of $157.40 and a 200-day simple moving average of $175.17. The firm has a market capitalization of $5.41 billion, a price-to-earnings ratio of 106.76 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.30 EPS. Equities analysts predict that Krystal Biotech, Inc. will post 3.22 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).